Characterization and analysis of the outcome of adults with acute myeloid leukemia treated in a Brazilian University hospital over three decades
| Autor: | Monique Loureiro, M Nucci, Rodrigo Portugal, Wolmar Pulcheri, J.T. Souto Filho |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Survival Physiology medicine.medical_treatment Immunology Biophysics Tumor burden Biochemistry Disease-Free Survival Young Adult Internal medicine medicine Humans General Pharmacology Toxicology and Pharmaceutics Single institution Child lcsh:QH301-705.5 Aged Retrospective Studies Aged 80 and over Chemotherapy lcsh:R5-920 Acute myeloid leukemia business.industry General Neuroscience Multilineage dysplasia Myeloid leukemia Induction Chemotherapy Cell Biology General Medicine Middle Aged medicine.disease University hospital Prognosis Surgery Hospitalization Survival Rate Leukemia Myeloid Acute Leukemia Treatment Outcome lcsh:Biology (General) Female business lcsh:Medicine (General) Brazil Median survival |
| Zdroj: | Brazilian Journal of Medical and Biological Research, Vol 44, Iss 7, Pp 660-665 (2011) Brazilian Journal of Medical and Biological Research, Volume: 44, Issue: 7, Pages: 660-665, Published: JUL 2011 Brazilian Journal of Medical and Biological Research v.44 n.7 2011 Brazilian Journal of Medical and Biological Research Associação Brasileira de Divulgação Científica (ABDC) instacron:ABDC |
| Popis: | We evaluated the outcome of 227 patients with acute myeloid leukemia during three decades (period 1 - 1980's, N = 89; period 2 - 1990's, N = 73; period 3 - 2000's, N = 65) at a single institution. Major differences between the three groups included a higher median age, rates of multilineage dysplasia and co-morbidities, and a lower rate of clinical manifestations of advanced leukemia in recent years. The proportion of patients who received induction remission chemotherapy was 66, 75, and 85% for periods 1, 2, and 3, respectively (P = 0.04). The median survival was 40, 77, and 112 days, and the 5-year overall survival was 7, 13, and 22%, respectively (P = 0.01). The median disease-free survival was 266, 278, and 386 days (P = 0.049). Survival expectation for patients with acute myeloid leukemia has substantially improved during this 30-year period, due to a combination of lower tumor burden and a more efficient use of chemotherapy and supportive care. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|